WCLC 2023 Expert Perspectives

CE / CME

2023 World Conference on Lung Cancer: Expert Perspectives on Key Studies

Physician Assistants/Physician Associates: 1.50 AAPA Category 1 CME credits

Nurses: 1.50 Nursing contact hours

Physicians: maximum of 1.50 AMA PRA Category 1 Credits

Pharmacists: 1.50 contact hours (0.15 CEUs)

Released: November 17, 2023

Expiration: November 16, 2024

Matthew Gubens
Matthew Gubens, MD, MS, FASCO
Helena Yu
Helena Yu, MD

Activity

Progress
1 2
Course Completed

References

  1. Osimertinib [prescribing information]. Wilmington, DE: AstraZeneca; 2023.
  2. Noronha V, Patil VM, Joshi A, et al. Gefitinib versus gefitinib plus pemetrexed and carboplatin chemotherapy in EGFR-mutated lung cancer. J Clin Oncol. 2020;38:124-136.
  3. Miyauchi E, Morita S, Nakamura A, et al. Updated analysis of NEJ009: gefitinib-alone versus gefitinib plus chemotherapy for non-small-cell lung cancer with mutated EGFR. J Clin Oncol. 2022;40:3587-3592.
  4. Saito R, Sugawara S, Ko R, et al. Phase 2 study of osimertinib in combination with platinum and pemetrexed in patients with previously untreated EGFR-mutated advanced non-squamous non-small cell lung cancer: the OPAL Study. Eur J Cancer. 2023;185:83-93.
  5. Janne P, Planchard D, Cheng Y, et al. Osimertinib with/without platinum-based chemotherapy as first-line treatment in patients with EGFRm advanced NSCLC (FLAURA2). Presented at: 2023 International Association for the Study of Lung Cancer World Conference on Lung Cancer; September 9-12, 2023. Abstract PL03.13.
  6. Cho BC, Felip E, Spira AI, et al. Amivantamab plus lazertinib vs osimertinib as first-line treatment in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): primary results from MARIPOSA, a phase III, global, randomized, controlled trial. Presented at: European Society for Medical Oncology Congress 2023; October 20-24, 2023. Abstract LBA14.
  7. Hashimoto Y, Koyama K, Kamai Y, et al. A novel HER3-targeting antibody-drug conjugate, U3-1402, exhibits potent therapeutic efficacy through the delivery of cytotoxic payload by efficient internalization. Clin Cancer Res. 2019;25:7151-7161.
  8. Yu HA, Yang JC, Hayashi H, et al. HERTHENA-Lung01: a phase II study of patritumab deruxtecan (Patritumab deruxtecan) in previously treated metastatic EGFR-mutated NSCLC. Future Oncol. 2023;19:1319-1329.
  9. Janne PA, Baik C, Su WC, et al. Efficacy and safety of patritumab deruxtecan (patritumab deruxtecan) in EGFR inhibitor-resistant, EGFR-mutated non-small cell lung cancer. Cancer Discov. 2022;12:74-89.
  10. Yu HA, Goto Y, Hayashi H, et al. Patritumab deruxtecan (patritumab deruxtecan) in EGFR-mutated NSCLC following EGFR TKI and platinum-based chemotherapy: HERTHENA-Lung01. Presented at: 2023 International Association for the Study of Lung Cancer World Conference on Lung Cancer; September 9-12, 2023. Abstract OA05.03.
  11. Li BT, Smit EF, Goto Y, et al. Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer. N Engl J Med. 2022;386:241-251.
  12. Lee CS, Milone M, Seetharamu N. Osimertinib in EGFR-Mutated lung cancer: a review of the existing and emerging clinical data. Onco Targets Ther. 2021;14:4579-4597.
  13. Ríos-Hoyo A, Moliner L, Arriola E. Acquired mechanisms of resistance to osimertinib-the next challenge. Cancers (Basel). 2022;14:1931.
  14. Kim TM, Guarneri V, Jye VP, et al. Tepotinib + osimertinib in EGFR-mutant NSCLC with MET amplification following 1L osimertinib: INSIGHT 2 primary analysis. Presented at: 2023 International Association for the Study of Lung Cancer World Conference on Lung Cancer; September 9-12, 2023. Abstract OA21.05.
  15. Smit EF, Dooms C, Raskin J, et al. INSIGHT 2: a phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistance. Future Oncol. 2022;18:1039-1054.
  16. Gomatou G, Syrigos N, Kotteas E. Osimertinib resistance: molecular mechanisms and emerging treatment options. Cancers (Basel). 2023;15: 841.
  17. Sequist LV, Han JY, Ahn MJ, et al. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study. Lancet Oncol. 2020;21:373-386.
  18. Yang JJ, Fang J, Shu YQ, et al. A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR-mutated, MET-amplified advanced non-small-cell lung cancer. Invest New Drugs. 2021;39:477-487.
  19. McCoach CE, Yu A, Gandara DR, et al. Phase I/II study of capmatinib plus erlotinib in patients with MET-positive non-small-cell lung cancer. JCO Precis Oncol. 2021;1:PO.20.00279.
  20. Cho BC, Kim DW, Spira AI, et al. Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial. Nat Med. 2023;[Epub ahead of print].
  21. Amivantamab-vmjw [prescribing information]. Horsham, PA: Janssen; 2022.
  22. Mobocertinib [prescribing information]. Lexington, MA: Takeda; 2023.
  23. Shi Y, Zhang S, Hu X, et al. Safety, clinical activity, and pharmacokinetics of alflutinib (AST2818) in patients with advanced NSCLC with EGFR T790M mutation. J Thorac Oncol. 2020;15:1015-1026.
  24. Shi Y, Hu X, Zhang S, et al. Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study. Lancet Respir Med. 2021;9:829-839.
  25. Han B, Zhou C, Wu L, et al. Preclinical and preliminary clinical investigations of furmonertinib in NSCLC with EGFR exon 20 insertions (20ins). Presented at: European Society for Medical Oncology Congress 2021; September 16-21, 2021. Abstract 1210P.
  26. Zhang SS, Ou SI. Spotlight on furmonertinib (alflutinib, AST2818). The Swiss Army knife (del19, L858R, T790M, exon 20 insertions, “uncommon-G719X, S768I, L861Q”) among the third-generation EGFR TKIs? Lung Cancer (Auckl). 2022;13:67-73.
  27. Han B, Zhou C, Zheng W, et al. FAVOUR: a phase 1b study of furmonertinib, an oral, selective EGFR inhibitor, in patients with advanced NSCLC with EGFR Exon 20 insertions. Presented at: 2023 International Association for the Study of Lung Cancer World Conference on Lung Cancer; September 9-12, 2023. Abstract OA03.04.
  28. Zhou C, Ramalingam SS, Kim TM, et al. Treatment outcomes and safety of mobocertinib in platinum-pretreated patients with EGFR exon 20 insertion-positive metastatic non-small cell lung cancer: a phase 1/2 open-label nonrandomized clinical trial. JAMA Oncol. 2021;7:e214761.
  29. Wang M, Yang JC, Mitchell PL, et al. Sunvozertinib, a selective EGFR inhibitor for previously treated non-small cell lung cancer with EGFR exon 20 insertion mutations. Cancer Discov. 2022;12:1676-1689.
  30. Aggarwal C, Liu SV. Zipalertinib in EGFR exon 20-mutant non-small-cell lung cancer: drug development in a rare but crowded setting. J Clin Oncol. 2023;41:4200-4203.
  31. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: non-small cell lung cancer. v.4.2023. nccn.org. Accessed November 1, 2023.
  32. Entrectinib [prescribing information]. South San Francisco, CA: Genentech; 2023.
  33. Crizotinib [prescribing information]. New York, NY: Pfizer; 2023.
  34. Lorlatinib [prescribing information]. New York, NY: Pfizer; 2023.
  35. Drilon A, Ou SI, Cho BC, et al. Repotrectinib (TPX-0005) is a next-generation ROS1/TRK/ALK inhibitor that potently inhibits ROS1/TRK/ALK solvent- front mutations. Cancer Discov. 2018;8:1227-1236.
  36. Cho BC, Lin J, Camidge DR, et al. Pivotal topline data from the phase 1/2 TRIDENT-1 trial of repotrectinib in patients with ROS1+ advanced non-small cell lung cancer (NSCLC). Presented at: 2022 European Organisation for Research and Treatment of Cancer, National Cancer Institute, and American Association for Cancer Research Symposium on Molecular Targets and Cancer Therapeutics; October 26-28, 2022. Abstract 2LBA.
  37. Cho BC, Camidge DR, Lin JJ, et al. Repotrectinib in patients with ROS1 fusion-positive
    non-small cell lung cancer: update from the pivotal phase 1/2 TRIDENT-1 trial. Presented at: 2023 International Association for the Study of Lung Cancer World Conference on Lung Cancer; September 9-12, 2023. Abstract OA03.06.
  38. Frampton GM, Ali SM, Rosenzweig M, et al. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Cancer Discov. 2015;5:850-859.
  39. Capmatinib [prescribing information]. East Hanover, NJ: Novartis; 2023.
  40. Tepotinib [prescribing information]. Rockland, MA: Merck; 2021.
  41. Fujino T, Suda K, Mitsudomi T. Lung Cancer with MET exon 14 skipping mutation: genetic feature, current treatments, and future challenges. Lung Cancer (Auckl). 2021;12:35-50.
  42. Spira AI, Krebs M, Cho BC, et al. Amivantamab in non-small cell lung cancer (NSCLC) with MET exon 14 skipping (METex14) mutation: initial results from CHRYSALIS. Presented at: 2021 International Association for the Study of Lung Cancer World Conference on Lung Cancer; September 8-14, 2021. Abstract OA15.03.
  43. Krebs M, Spira AI, Cho BC, et al. Amivantamab in patients with NSCLC with MET exon 14 skipping mutation: updated results from the CHRYSALIS study. Presented at: 2022 American Society of Clinical Oncology Annual Meeting; June 3-7, 2022. Abstract 9008.
  44. Leighl NB, Cho BC, Hiret S, et al. Amivantamab in patients with advanced NSCLC and MET exon 14 skipping mutation: results from the CHRYSALIS study. Presented at: 2023 International Association for the Study of Lung Cancer World Conference on Lung Cancer; September 9-12, 2023. Abstract OA21.04.
  45. Goto K, Sang-We K, Kubo T, et al. Trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutant metastatic non-small cell lung cancer (NSCLC): interim results from the phase 2 DESTINY-Lung02 trial. Presented at: European Society for Medical Oncology Congress 2022; September 9-13, 2022. Abstract LBA55.
  46. Janne P, Goto Y, Kubo T, et al. Trastuzumab deruxtecan in patients with HER2-mutant metastatic non-small cell lung cancer: primary results of DESTINY-Lung02. Presented at: 2023 International Association for the Study of Lung Cancer World Conference on Lung Cancer; September 9-12, 2023. Abstract MA13.10.
  47. Goto K, Goto Y, Kubo T, et al. Trastuzumab deruxtecan in patients with HER2-mutant metastatic non-small-cell lung cancer: primary results from the randomized, phase II DESTINY-Lung02 trial. J Clin Oncol. 2023;[Epub ahead of print].
  48. Heist RS, Guarina M, Masters G, et al. Therapy of advanced non–small-cell lung cancer with an SN-38-anti-Trop-2 drug conjugate, sacituzumab govitecan. J Clin Oncol. 2017;35:2790-2797.
  49. Bardia A, Messersmith WA, Kio EA, et al. Sacituzumab govitecan-hziy, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial. Ann Oncol. 2021;32:746-756.
  50. Shimizu T, Sands J, Yoh K, et al. First-in-human, phase I dose-escalation and dose-expansion study of trophoblast cell-surface antigen 2-directed antibody-drug conjugate datopotamab deruxtecan in non-small-cell lung cancer: TROPION-PanTumor01. J Clin Oncol. 2023;41:4678-4687.
  51. Drago JZ, Modi S, Chandarlapaty S. Unlocking the potential of antibody-drug conjugates for cancer therapy. Nat Rev Clin Oncol. 2021;18:327-344.
  52. Cho BC, Dobs MC, Reyes Cabanillas R, et al. Sacituzumab govitecan + pembrolizumab in 1L metastatic non-small cell lung cancer: preliminary results of the EVOKE-02 study. Presented at: 2023 International Association for the Study of Lung Cancer World Conference on Lung Cancer; September 9-12, 2023. Abstract OA05.04.
  53. Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375:1823-1833.
  54. Goto Y, Su W, Levy BP, et al. TROPION-Lung02: datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) in advanced non-small cell lung cancer (aNSCLC). Presented at: 2023 American Society of Clinical Oncology Annual Meeting; June 2-6, 2023. Abstract 9004.
  55. Durvalumab [prescribing information]. Wilmington, DE: AstraZeneca; 2023.
  56. Papadopoulos KP, Bruno DS, Kitazono S, et al. Datopotamab deruxtecan (Dato-DXd) + durvalumab ± carboplatin in advanced/metastatic NSCLC: initial results from the phase 1b TROPION-Lung04 study. Presented at: 2023 International Association for the Study of Lung Cancer World Conference on Lung Cancer; September 9-12, 2023. Abstract OA05.06.
  57. Giladi M, Schneiderman RS, Voloshin T, et al. Mitotic spindle disruption by alternating electric fields leads to improper chromosome segregation and mitotic catastrophe in cancer cells. Sci Rep. 2015;5:18046.
  58. Mun EJ, Babiker HM, Weinberg U, et al. Tumor-treating fields: a fourth modality in cancer treatment. Clin Cancer Res. 2018;24:266-275.
  59. NovoTTF-100A System [prescribing information]. Portsmouth, NH: Novocure; 2015.
  60. NovoTTF-100L System [prescribing information]. Portsmouth, NH: Novocure; 2019.
  61. Leal T, Kotecha R, Ramlau R, et al. Tumor treating field (TTFields) therapy with standard of care (SOC) in metastatic non-small cell lung cancer (mNSCLC) following platinum failure: randomized, phase 3 LUNAR study. Presented at: 2023 American Society of Clinical Oncology Annual Meeting; June 2-6, 2023. Abstract LBA9005.
  62. Leal T, Kotecha R, Ramlau R, et al. TTFields and immune-checkpoint inhibitor in metastatic non-small cell lung cancer: PD-L1 subgroups in the phase 3 LUNAR study. Presented at: 2023 International Association for the Study of Lung Cancer World Conference on Lung Cancer; September 9-12, 2023. Abstract OA22.05.
  63. Cemiplimab [prescribing information]. Tarrytown, NY: Regeneron; 2023.
  64. Sezer A, Kilickap S, Gümüş M, et al. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. Lancet. 2021;397:592-604.
  65. Gogishvili M, Melkadze T, Makharadze T, et al. Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial. Nat Med. 2022;28:2374-2380.
  66. Makharadze T, Gogishvili M, Melkadze T, et al. Cemiplimab plus chemotherapy versus chemotherapy alone in advanced NSCLC: 2-year follow-up from the phase 3 EMPOWER-Lung 3 part 2 trial. J Thorac Oncol. 2023;18:755-768.
  67. Baramidze A, Gessner C, Gogishvili M, et al. Cemiplimab-based treatment in advanced NSCLC with liver metastases: updated analysis from EMPOWER-Lung 1 and EMPOWER-Lung 3. Presented at: 2023 International Association for the Study of Lung Cancer World Conference on Lung Cancer; September 9-12, 2023. Abstract P2.06-01.
  68. Atezolizumab [prescribing information]. South San Francisco, CA: Genentech; 2023.
  69. Felip E, Altorki N, Zhou C, et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet. 2021;398:1344-1357.
  70. Pembrolizumab [prescribing information]. Rahway, NJ: Merck; 2023.
  71. O'Brien M, Paz-Ares L, Marreaud S, et al. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial. Lancet Oncol. 2022;23:1274-1286.
  72. Nivolumab [prescribing information]. Princeton, NJ: Bristol Myers Squibb; 2023.
  73. Forde PM, Spicer J, Lu S, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022;386:1973-1985.
  74. Heymach JV, Harpole D, Mitsudomi T, et al. AEGEAN: a phase 3 trial of neoadjuvant durvalumab + chemotherapy followed by adjuvant durvalumab in patients with resectable NSCLC. Presented at: 2023 American Association for Cancer Research Annual Meeting 2023; April 14-19, 2023. Abstract CT005.
  75. Mitsudomi T, Heymach JV, Reck M. Surgical outcomes with neoadjuvant durvalumab + chemotherapy followed by adjuvant durvalumab in resectable NSCLC (AEGEAN). Presented at: 2023 International Association for the Study of Lung Cancer World Conference on Lung Cancer; September 9-12, 2023. Abstract OA12.05.
  76. Spicer J, Wang C, Tanaka F, et al. Surgical outcomes from the phase 3 CheckMate 816 trial: nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC). Presented at: 2021 American Society of Clinical Oncology Annual Meeting; June 4-8, 2021. Abstract 8503.
  77. Chang JY, Mehran RJ, Feng L, et al. Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery. Lancet Oncol. 2021;22:1448-1457.
  78. Spigel DR, Faivre-Finn C, Gray JE, et al. Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. J Clin Oncol. 2022;40:1301-1311.
  79. Chang JY, Lin SH, Dong W, et al. Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial. Lancet. 2023;402:871-881.
  80. Chang JY, Lin SH, Dong DL, et al. Stereotactic ablative radiotherapy with or without immunotherapy for early stage or isolated lung parenchymal recurrent node negative NSCLC:

an open label, randomized, phase 2 trial. Presented at: 2023 International Association for the Study of Lung Cancer World Conference on Lung Cancer; September 9-12, 2023. Abstract OA12.04.

  1. Dong P, Xiong Y, Yue J, Hanley SJB, Watari H. B7H3 as a promoter of metastasis and promising therapeutic target. Front Oncol. 2018;8:264.
  2. Picarda E, Ohaegbulam KC, Zang X. Molecular pathways: targeting B7-H3 (CD276) for human cancer immunotherapy. Clin Cancer Res. 2016;22:3425-3431.
  3. Kontos F, Michelakos T, Kurokawa T, et al. B7-H3: an attractive target for antibody-based immunotherapy. Clin Cancer Res. 2021;27:1227-1235.
  4. Johnson ML, Doi T, Piha-Paul SA, et al. A phase I/II multicenter, first-in-human study of DS-7300 (B7-H3 DXd-ADC) in patients (pts) with advanced solid tumors. Presented at: European Society for Medical Oncology Congress 2021; September 16-21, 2021. Abstract 5130.
  5. Doi T, Patel M, Falchook GS, et al. DS-7300 (B7-H3 DXd antibody-drug conjugate [ADC]) shows durable antitumor activity in advanced solid tumors: extended follow-up of a phase I/II study. Presented at: European Society for Medical Oncology Congress 2022; September 9-13, 2022. Abstract 4530.
  6. Johnson M, Awad M, Koyama T, et al. Ifinatamab deruxtecan (I-DXd; DS-7300) in patients with refractory SCLC: a subgroup analysis of a phase 1/2 study. Presented at: 2023 International Association for the Study of Lung Cancer World Conference on Lung Cancer; September 9-12, 2023. Abstract OA05.05.
  7. Paz-Ares L, Champiat S, Lai WV, et al. Tarlatamab, a first-in-class DLL3-targeted bispecific T-cell engager, in recurrent small-cell lung cancer: an open-label, phase I study. J Clin Oncol. 2023;41:2893-2903.
  8. Johnson ML, Dy GK, Mamdani H, et al. Interim results of an ongoing phase 1/2a study of HPN328, a tri-specific, half-life extended, DLL3-targeting, T-cell engager, in patients with small cell lung cancer and other neuroendocrine cancers. Presented at: 2022 American Society of Clinical Oncology Annual Meeting; June 3-7, 2022. Abstract 8566.
  9. Wermke M, Felip E, Kuboki Y, et al. First-in-human dose-escalation trial of BI 764532, a delta-like ligand 3 (DLL3)/CD3 IgG-like T-cell engager in patients (pts) with DLL3-positive (DLL3+) small-cell lung cancer (SCLC) and neuroendocrine carcinoma (NEC). Presented at: 2023 American Society of Clinical Oncology Annual Meeting; June 2-6, 2023. Abstract 8502.
  10. Spicer JD, Gao S, Liberman M, et al. Overall survival in the KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC). Presented at: European Society for Medical Oncology Congress 2023; October 20-24, 2023. Abstract LBA56.
  11. Gray JE, Ahn M-J, Oxnard GR, et al. Early clearance of plasma Epidermal Growth Factor Receptor mutations as a predictor of outcome on osimertinib in advanced non–small cell lung cancer; exploratory analysis from AURA3 and FLAURA. Clin Cancer Res. 2023;29:3340-3351.